Literature DB >> 1613514

Reduced neuropeptide Y concentrations in suicide brain.

P S Widdowson1, G A Ordway, A E Halaris.   

Abstract

Neuropeptide Y (NPY) was measured in postmortem brain tissue from victims of suicide and from individuals dying a sudden natural or accidental death (controls). Concentrations of NPY-immunoreactivity were measured by radioimmunoassay in frontal cortex (BA 10), temporal cortex (BA 22), caudate nucleus, and cerebellum. Concentrations of NPY-immunoreactivity were significantly lower in postmortem frontal cortex (-14%) and caudate nucleus (-27%) from suicide victims compared with age-matched controls. A subgroup of suicides with evidence of a history of depression revealed more robust reductions in concentrations of NPY-immunoreactivity in frontal cortex and caudate nucleus, as did four individuals who died from natural causes and also were described as having a possible history of depression. Concentrations of NPY-immunoreactivity in temporal cortex and cerebellum from victims of suicide or from the subgroup of subjects with a possible history of depression were not significantly different from those of age-matched controls. We suggest there is a deficit in the brain NPY system leading to region-specific reductions in peptide concentrations in subjects who have a history of depression.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1613514     DOI: 10.1111/j.1471-4159.1992.tb08877.x

Source DB:  PubMed          Journal:  J Neurochem        ISSN: 0022-3042            Impact factor:   5.372


  28 in total

1.  Effects of electroconvulsive stimuli and MK-801 on neuropeptide Y, neurokinin A, and calcitonin gene-related peptide in rat brain.

Authors:  A A Mathé; S Gruber; P A Jiménez; E Theodorsson; C Stenfors
Journal:  Neurochem Res       Date:  1997-05       Impact factor: 3.996

Review 2.  Tobacco addiction and the dysregulation of brain stress systems.

Authors:  Adrie W Bruijnzeel
Journal:  Neurosci Biobehav Rev       Date:  2012-03-03       Impact factor: 8.989

3.  Human NPY promoter variation rs16147:T>C as a moderator of prefrontal NPY gene expression and negative affect.

Authors:  Wolfgang H Sommer; Jessica Lidström; Hui Sun; Derek Passer; Robert Eskay; Stephen C J Parker; Stephanie H Witt; Ulrich S Zimmermann; Vanessa Nieratschker; Marcella Rietschel; Elliott H Margulies; Miklós Palkovits; Manfred Laucht; Markus Heilig
Journal:  Hum Mutat       Date:  2010-08       Impact factor: 4.878

Review 4.  From synapse to nucleus: novel targets for treating depression.

Authors:  Herbert E Covington; Vincent Vialou; Eric J Nestler
Journal:  Neuropharmacology       Date:  2009-12-17       Impact factor: 5.250

Review 5.  An overview of the neurobiology of suicidal behaviors as one meta-system.

Authors:  M Sokolowski; J Wasserman; D Wasserman
Journal:  Mol Psychiatry       Date:  2014-09-02       Impact factor: 15.992

6.  Neuropeptide Y impairs the acquisition of conditioned defeat in Syrian hamsters.

Authors:  Tiara Lacey; Josiah Sweeting; Rody Kingston; Michael Smith; Chris M Markham
Journal:  Neurosci Lett       Date:  2018-10-09       Impact factor: 3.046

7.  Brain monoaminergic and neuropeptidergic variations in human aging.

Authors:  B Arranz; K Blennow; R Ekman; A Eriksson; J E Månsson; J Marcusson
Journal:  J Neural Transm (Vienna)       Date:  1996       Impact factor: 3.575

8.  Npy deletion in an alcohol non-preferring rat model elicits differential effects on alcohol consumption and body weight.

Authors:  Bin Qiu; Richard L Bell; Yong Cao; Lingling Zhang; Robert B Stewart; Tamara Graves; Lawrence Lumeng; Weidong Yong; Tiebing Liang
Journal:  J Genet Genomics       Date:  2016-04-29       Impact factor: 4.275

9.  Neuropeptides involved in the pathophysiology of schizophrenia and major depression.

Authors:  David De Wied; Hein O. Sigling
Journal:  Neurotox Res       Date:  2002 Aug-Sep       Impact factor: 3.911

10.  Neuropeptide Y and representation of salience in human nucleus accumbens.

Authors:  Katherine G Warthen; Benjamin Sanford; Kendal Walker; Keith G Jones; Mike Angstadt; Chandra Sripada; David Goldman; Jon-Kar Zubieta; Robert C Welsh; Margit Burmeister; Brian J Mickey
Journal:  Neuropsychopharmacology       Date:  2018-10-02       Impact factor: 7.853

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.